Clinical Trials Directory

Trials / Completed

CompletedNCT02422927

Nutraceutical Combination in Patients With Low-grade Systemic Inflammation

Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
100 (actual)
Sponsor
University Of Perugia · Academic / Other
Sex
All
Age
25 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The investigators tested if a nutraceutical combination with red yeast rice, berberine and policosanol (NC) can significantly modify inflammation, lipid profile and markers of endothelial injury (endothelial microparticles) in subjects with elevated levels of high-sensitivity C-reactive protein (hsCRP).

Detailed description

Will be included in the study 100 subjects with suboptimal LDL cholesterol levels (LDL 100-160 mg / dL) and hsCRP levels\> 2 mg / L, divided into two groups of equal numbers, matched by by sex and age, randomized to receive a nutraceutical combination containing red yeast 200 mg, berberine 500 mg and policosanol 10 mg (NC) in combination with a low-cholesterol diet (\<200 mg / day) or a low-cholesterol diet only (Standard of Care - SOC). All subjects at the time of inclusion in the study protocol will be prescribed the SOC for a period of 30 days (Lipid Stabilization Period: LSP); After 30 days LSP it will be performed randomization in the two intervention arms: NC + SOC or SOC.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNutraceutical Combinationred yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
OTHERStandard of Carelow-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
OTHERPlaceboplacebo

Timeline

Start date
2014-07-01
Primary completion
2015-01-01
Completion
2015-02-01
First posted
2015-04-22
Last updated
2015-04-22

Source: ClinicalTrials.gov record NCT02422927. Inclusion in this directory is not an endorsement.